Gutzeit, CindyGrasset, Emilie K.Matthews, Dean B.Maglione, Paul J.Britton, Graham J.Miller, HalleyMagri, GiulianaTomalin, LewisStapylton, MatthewCanales Herrerias, PabloSominskaia, MusiaGuzman, MauricioPybus, MarcTejedor Vaquero, SoniaRadigan, LinTachó Piñot, RoserMartín Nalda, AndreaGarcía Prat, MarinaMartínez Gallo, MónicaDieli Crimi, RominaClemente, José C.Mehandru, SaurabhSuárez Farinas, MayteFaith, Jeremiah J.Cunningham-Rundles, CharlotteCerutti, Andrea2025-03-062025-03-062025-02-12https://hdl.handle.net/2445/219500The gut microbiota enhances systemic immunoglobulin G (IgG) responses to vaccines, but it is unknown whether this effect involves IgA, which coats intestinal microbes. That IgA may amplify postimmune IgG production is suggested by the impaired IgG response to pneumococcal vaccines in some IgA-deficient patients. Here, we found that antipneumococcal but not total IgG production was impaired in mice with IgA deficiency. The positive effect of gut IgA on antipneumococcal IgG responses started very early in life and could implicate gut bacteria, as these responses were attenuated in germ-free mice recolonized with gut microbes from IgA-deficient donors. IgA could exert this effect by constraining the systemic translocation of gut antigens, which was associated with chronic immune activation, including T cell overexpression of programmed cell death protein 1 (PD-1). This inhibitory receptor may attenuate antipneumococcal IgG production by causing B cell hyporesponsiveness, which improved upon anti-PD-1 treatment. Thus, gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses15 p.application/pdfengcc-by (c) Gutzeit, C et al., 2025http://creativecommons.org/licenses/by/4.0/Immunoglobulina GMicrobiota intestinalImmunoglobulina AVacuna antipneumocòccicaImmunoglobulin GGastrointestinal microbiomeImmunoglobulin APneumococcal vaccineinfo:eu-repo/semantics/article7559082025-03-06info:eu-repo/semantics/openAccess39937896